A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2

[1]  S. Takai,et al.  Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans , 2015, The Journal of Immunology.

[2]  O. Boyman,et al.  Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. , 2014, Current opinion in chemical biology.

[3]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[4]  V. Barnaba,et al.  Induction, control, and plasticity of Treg cells: The immune regulatory network revised? , 2013, European journal of immunology.

[5]  Melody J Eide,et al.  Update on the current state of melanoma incidence. , 2012, Dermatologic clinics.

[6]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[7]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[8]  T. Giese,et al.  In vivo Expansion of Naïve CD4+CD25high FOXP3+ Regulatory T Cells in Patients with Colorectal Carcinoma after IL-2 Administration , 2012, PloS one.

[9]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[10]  J. Sprent,et al.  The role of interleukin-2 in memory CD8 cell differentiation. , 2010, Advances in experimental medicine and biology.

[11]  S. Stepkowski,et al.  Expanding and converting regulatory T cells: a horizon for immunotherapy , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[12]  S. Steinberg,et al.  High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.

[13]  H. Ljunggren,et al.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy , 2008, Cancer Immunology, Immunotherapy.

[14]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[15]  S. Hirohashi,et al.  FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.

[16]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[17]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Antonio Lanzavecchia,et al.  Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming , 2004, Nature Immunology.

[19]  W. Knaus,et al.  CXC Chemokine Receptor 3 Expression by Activated CD8+ T cells Is Associated with Survival in Melanoma Patients with Stage III Disease , 2004, Cancer Research.

[20]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[21]  Ethan M. Shevach,et al.  Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.

[22]  M. Atkins,et al.  Application of IL-2 and other cytokines in renal cancer , 2004, Expert opinion on biological therapy.

[23]  E. Shevach,et al.  Activation requirements for the induction of CD4+CD25+ T cell suppressor function , 2004, European journal of immunology.

[24]  U. Koszinowski,et al.  Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses , 2003 .

[25]  U. Koszinowski,et al.  Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. , 2003, Immunity.

[26]  S. Rosenberg.  Progress in the development of immunotherapy for the treatment of patients with cancer , 2001, Journal of internal medicine.

[27]  E. Seifried,et al.  Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. , 2001, Journal of hematotherapy & stem cell research.

[28]  S. Ziegler,et al.  The activation antigen CD69 , 1994, Stem cells.

[29]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.